Navigation Links
Mark Rinker Named Vice President of Sales for Blaine Pharmaceuticals
Date:11/12/2007

New direction for Blaine Pharmaceuticals

CINCINNATI, Nov. 12 /PRNewswire/ -- Blaine Pharmaceuticals announced today that it has promoted Mark Rinker to Vice President of Sales. Mark will be responsible for all trade relations, market development activities, and sales management as well as evaluating and developing new products to complement the existing Blaine product portfolio.

During his tenure at Blaine Pharmaceuticals, the company has gained significant ground as an over-the-counter (OTC) pharmaceutical company. Blaine's leading product, Mag-Ox 400(R), has expanded distribution in all major food, drug, and mass channels. In 2006, DiaSense(R), a branded line of diabetes supplements was introduced. In 2007, ReliaDose(R) (innovative pediatric medicine delivery system) has been placed in over 27,000 retail locations in the U.S. and internationally.

Mark was hired by Blaine Pharmaceuticals as the Director of International Sales where he helped catapult the company's international presence for Mag-Ox 400(R), DiaSense(R), and ReliaDose(R), in Canada, Japan, South Africa, Central America, Mexico and Korea. Since Mark has been highly involved with the strategic direction of Blaine for the last year, he is armed with knowledge that will be critical in his new position of Vice President of Sales.

Prior to Blaine, Mark served as director of Canadian operations for Omron Healthcare. At Omron, Rinker successfully established Canadian operations. Prior to Omron, Rinker served as a national sales manager with Magna-Pak, Inc., and as a business development manager at Becton Dickinson Canada. Mark graduated from University of Western Ontario with a Bachelor of Administration.

With his new position, Mark will report to Vince Gilday, the Chief Operating Officer. In his new capacity he will work closely with Dreama Kirby, the Chief Marketing Officer to set a strategic direction which focuses on expanding Blaine's market share for its lead products. Now that Blaine has secured significant retail distribution, its objective is to drive the sales of these branded products with considerably more marketing support. These changes within the organization will allow for unprecedented growth of its brands over the next year.

About Blaine Pharmaceuticals

Blaine Pharmaceuticals, founded in 1955, specializes in the development and acquisition of consumer brands with significant value and unrealized potential. Blaine builds sustainable brands by creating consumer demand through recommendations from healthcare professionals. The company's flagship product, Mag-Ox 400(R), is the #1 selling magnesium brand. Other products include the DiaSense(R) family of nutritional supplements and ReliaDose(R), a pediatric medicine-delivery system.

Blaine is committed to cultivating relationships with physicians, pharmacists, patients, wholesalers, retailers, and business partners to build brands and lay the foundation for future endeavors. For more information, visit http://www.blainepharma.com .


'/>"/>
SOURCE Blaine Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
3. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
4. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
5. New Director of Nursing Practice Named for Nurses Association
6. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
7. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
8. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
9. Keith Taft Named General Manager of UltraTape Industries
10. AIUM CEO named among most influential in radiology
11. Top Twenty Health Plan Websites Named by TheRatingsGuy.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... to patients suffering from chronic pelvic pain. In addition to oncology services, ... pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during menstruation), uterine fibroids, and ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... awards program which recognizes organizations that demonstrate the core values of business innovation, ... categories. , “As a global company, we are expanding our presence in all ...
(Date:8/16/2017)... ... , ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen F. ... an insatiable appetite for God’s Word. , “I froze between the half walls, shelves on ... of oatmeal. I have one to this day on proud display in my dining room ...
(Date:8/15/2017)... ... ... city of Los Angeles is a west coast style fashion center as well as a ... website that spotlights fashion news from Los Angeles and around the world, is sharing clothing ... to the senior editor of latsl.com , “For a business that is known for ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics ... Dallas, Texas , has received notice from ... National Institutes of Health (NIH) that it has been ... grant totaling over $650,000 in 2017 with an additional ... CerSci,s Investigational New Drug application of their lead non-opioid ...
Breaking Medicine Technology: